latest news releases from the newsroom
Interland Partners with Ambassador Yellow Pages
ATLANTA, Nov. 10, 2005 (PRIMEZONE) -- Interland (Nasdaq:INLD), a leading provider of websites and online services for small and medium-sized businesses (SMBs), today announced that it partnered with Ambassador Yellow Pages, the fastest-growing directory publisher in New York City, to sell website design and hosting services to Ambassador's customer base.
Hana Biosciences to Present At the Noble Financial Group Small-Cap Conference
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2005 (PRIMEZONE) -- Hana Biosciences (AMEX:HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, will present at the Noble Financial Group Small Cap Conference, at 9:45 a.m. ET in the Elvis Presley Green Room on November 11, 2005. The forum is being held at the Seminole Hard Rock Hotel and Casino in Hollywood, Florida.
Skandia to Present Interim Report on 15 November 2005
STOCKHOLM, Sweden, Nov. 10, 2005 (PRIMEZONE) -- Skandia's board has decided to bring forward the publication of Skandia's third quarter interim report. The Board feels that it is important that Skandia's shareholders gain access to as complete information as possible on which to base their decisions regarding Old Mutual's offer.
ViroPharma Announces That Treatment With HCV-796 Reduces Hepatitis C Virus Levels
EXTON, Pa., Nov. 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced preliminary results from a Phase 1b proof of concept study with HCV-796, an orally dosed hepatitis C (HCV) viral polymerase inhibitor with the potential to interfere with the replication of hepatitis C virus, that is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE). In this trial, HCV-796 demonstrated antiviral effects in adult patients with chronic hepatitis C infection. The patient cohort with the highest exposure to HCV-796 achieved a peak mean HCV viral load reduction of 1.4 log10, or 96 percent, on day four of a 14 day dosing period. HCV-796 was found to be generally well tolerated, with favorable pharmacokinetics and no dose-limiting toxicities.
Norsk Hydro Sale of Shareholding in Biomar Holding A/S
OSLO, Norway, Nov. 10, 2005 (PRIMEZONE) -- Norsk Hydro ASA has today sold 7,569,990 shares in Biomar Holding A/S, representing an ownership interest of 68,82%, to Schouw & Co., a company listed on the Copenhagen Stock Exchange. The price obtained was DKK 118 per share.